Kytopen Corp.

CAMBRIDGE, Mass. and SAN FRANCISCO, April 7, 2026 /PRNewswire/ -- Kytopen Corp., a leader in non-viral, continuous flow cellular engineering, today announced a Series B financing led by Telegraph Hill Partners, with participation from existing investors. The funding will accelerate Kytopen's global commercial expansion and drive further adoption of its Flowfect® technology platform across the U.S. and Europe. As part of the investment, Telegraph Hill Partners will join Kytopen's Board of Directors. Kytopen's continuous flow transfection technology combines mechanical, electrical, and chemical forces to rapidly engineer hundreds of billions of healthy, high-quality cells in minutes. Designed for flexibility and scalability, the platform integrates seamlessly into closed GMP workflows, and the gentleness of the technology supports the full spectrum of cell therapy modalities. Its Flowfect Tx® GMP and Flowfect Discover™ 96-well systems enable a streamlined path from feasibility and optimization to clinical and commercial-scale manufacturing. Through its strategic partnerships, Kytopen will advance a new generation of cell therapies designed to revolutionize treatment across multiple disease areas. "Kytopen's Flowfect technology has demonstrated the ability to genetically modify a broad range of therapeutic cell types in higher quantities, with better cell health and with lower cost than existing methods" said Matthew Mackowski, Chairman, Managing Director at Telegraph Hill Partners. "Adoption of technologies like Kytopen's will be essential to achieving broader community access to potentially curative cell therapies by lowering costs, shortening turn-around-time, and reducing variability." "We welcome Telegraph Hill Partners to our investor base at this pivotal stage," said Michael Chiu, CEO of Kytopen. "With strong and growing customer demand, this investment enables us to scale globally while continuing to invest in the infrastructure needed to support our partners in delivering cost-effective, advanced cell therapies worldwide." For further information: Kytopen: Investor Contact: Michael Chiu PhD., CEO [email protected] Business and Corporate Development Contact: Kevin Gutshall, CCO [email protected] About Kytopen: The innovative leader in non-viral, continuous flow cellular engineering technologies, Kytopen, headquartered in Cambridge, Massachusetts, is transforming how cell therapies are manufactured by maximizing yields, delivering hundreds of billions of engineered cells in minutes – faster than any other technology – and thereby accelerating the discovery, development, and manufacture of advanced engineered cell therapies. Its Flowfect® cellular engineering technology is highly tunable, gentle on cells, and has demonstrated performance across a range of cell types, payloads, and therapeutic applications. Kytopen has recently disclosed strategic partnerships with industry-leading biotechnology companies, contract development and manufacturing organizations (CDMOs), and cell therapy-focused medical centers. Kytopen continues to engage strategic partners and is committed to enabling their partners' success by providing innovative technology and developing close collaborative relationships to bring lifesaving, next generation cell therapies to patients worldwide. About Telegraph Hill Partners: Telegraph Hill Partners, founded in 2001 and based in San Francisco, CA, invests in commercial stage life science, medical technology, and healthcare companies. For more information, please see . SOURCE Kytopen 21% more press release views with Request a Demo

Collaboration will investigate how continuous flow cellular engineering and donor-to-dose manufacturing expertise may advance scalable, non-viral processes for next-generation cell therapies. CAMBRIDGE, Mass. and SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- Kytopen Corp., a leader in continuous flow cellular engineering, and Excellos, Inc., a cell therapy CDMO and member of Blood Centers of America (BCA), today announced that the two companies are exploring a collaboration to advance non-viral cell therapy manufacturing technologies. The collaboration will focus on assessing the compatibility of Kytopen's Flowfect Tx® platform with Excellos' donor-to-dose manufacturing model and deep cell characterization capabilities. Together, the companies aim to evaluate opportunities to enhance process consistency, scalability, and overall cell quality in the development of next-generation cell-based therapies. Both organizations share a commitment to accelerating the translation of scientific innovation into practical, patient-focused manufacturing solutions. This strategic initiative embodies our shared vision — seeking new ways to streamline complex workflows and improve outcomes for developers of advanced cell therapies. "Kytopen's Flowfect® technology represents an exciting advancement in non-viral cellular engineering, and we're eager to explore how it could complement our donor-to-dose expertise," said Tom VanCott, CEO of Excellos. "Excellos' deep expertise in integrated manufacturing and advanced cell characterization capabilities make them an ideal partner in demonstrating how the Flowfect Tx® GMP platform enables scalable, consistent, and high-quality production of engineered cells." said Kevin Gutshall, Chief Commercial Officer at Kytopen. "We envision a future where advanced treatments become part of everyday healthcare, and our combined approach is designed to get us there." The initial work will focus on identifying areas of scientific and operational synergy, with the potential for future collaboration as development priorities converge. These proof of principle initiatives aim to generate deeper insights into the biological and process complexities that are not yet fully understood. For further information: Kytopen: Investor Contact: Michael Chiu PhD., CEO [email protected] Business and Corporate Development Contact: Kevin Gutshall, CCO [email protected] About Excellos Excellos is a cell therapy-focused CDMO leveraging deep scientific expertise, advanced cell characterization, and a unique donor-to-dose model to accelerate the development and manufacture of cell-based therapeutics. Excellos provides custom cGMP services that help reduce variability, improve reproducibility, and enhance translational success. Learn more at . About Kytopen The innovative leader in non-viral, continuous flow cellular engineering technologies, Kytopen, headquartered in Cambridge, Massachusetts, is transforming how cell therapies are manufactured by maximizing yields, delivering hundreds of billions of engineered cells in minutes – faster than any other technology – and thereby accelerating the discovery, development, and manufacture of advanced engineered cell therapies. Its Flowfect® cellular engineering technology is highly tunable, gentle on cells, and has demonstrated performance across a range of cell types, payloads, and therapeutic applications. Kytopen has recently disclosed strategic partnerships with industry-leading biotechnology companies, contract development and manufacturing organizations (CDMOs), and cell therapy-focused medical centers. Kytopen continues to engage strategic partners and is committed to enabling their partners' success by providing innovative technology and developing close collaborative relationships to bring lifesaving, next generation cell therapies to patients worldwide. SOURCE Kytopen 21% more press release views with Request a Demo

Kytopen Corp., a cellular engineering technology company based in Cambridge, Massachusetts, said it has entered a collaboration with BlueWhale Bio , a Maryland-based company focused on immune cell therapy manufacturing. The partnership will develop a non-viral manufacturing workflow designed to reduce production bottlenecks and accelerate the delivery of engineered cell therapies to patients, according to the announcement. The companies said the effort addresses current challenges facing CAR-T therapies, including vein-to-vein times of three to five weeks, high costs, and safety risks. The proposed workflow combines BlueWhale Bio’s Synecta CDNPs, which mimic antigen-presenting cells to activate T cells ex vivo, with Kytopen’s Flowfect continuous flow cellular engineering system, which integrates mechanical, electrical, and chemical forces to optimize transfection efficiency and cell viability. Kytopen said Flowfect can process hundreds of billions of cells within minutes, while BlueWhale Bio’s Synecta CDNPs are compatible with both viral and non-viral delivery methods. Together, the companies contend these technologies create a streamlined manufacturing process to yield higher numbers of viable engineered cells. “We believe this partnership represents a pivotal step forward in personalized cell therapy — bringing us significantly closer to drastically reduced vein-to-vein times for lifesaving treatments,” Kevin Gutshall, Kytopen’s chief commercial officer, said in a statement. According to the companies, both technologies are already in use. Synecta CDNPs are supporting an investigator-initiated Phase I clinical trial, and Kytopen’s Flowfect Tx platform is being used by partners with multiple therapies advancing toward investigational new drug submissions.